Clinical and laboratory features between anti-TIF1γ dermatomyositis with and without malignancy: 37 case series and a review

被引:0
|
作者
Tang, Ke-yun [1 ]
Zhang, Han-lin [1 ]
Zhang, Xin-yi [2 ,3 ]
Jin, Hong-zhong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Dermatol, State Key Lab Complex Severe & Rare Dis, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[2] Yale Sch Med, Dept Internal Med, New Haven, CT USA
[3] Yale Sch Med, Dept Cellular & Mol Physiol, New Haven, CT USA
来源
JOURNAL OF DERMATOLOGY | 2024年 / 51卷 / 12期
关键词
anti-TIF1 gamma autoantibody; clinical significance; dermatomyositis; malignancy; TIF1; gamma; IDIOPATHIC INFLAMMATORY MYOPATHIES; AMYOPATHIC DERMATOMYOSITIS; CANCER; MYOSITIS; AUTOANTIBODY; ADULT; CLASSIFICATION; IDENTIFICATION; POLYMYOSITIS; ANTIBODIES;
D O I
10.1111/1346-8138.17426
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We aimed to analyze the clinical profile and malignancy indicators in dermatomyositis (DM) with anti-transcriptional intermediary factor 1 antibody (anti-TIF1 gamma-Ab). A comparison was made between clinical information of anti-TIF1 gamma DM patients with and without malignancy. Additionally, a review of the literature on anti-TIF1 gamma DM and malignancy was conducted by searching PubMed and EMBASE databases. In our cohort of 37 patients, 27.0% (10/37) developed malignancy. The timeframe during which these 10 patients developed malignancy ranged from 21 months prior to the diagnosis of DM to 36 months following the diagnosis of DM. Specifically, one patient was diagnosed with breast cancer at the age of 36. Comparing the groups with and without malignancy, we found that age over 65 years (40% vs 7.4%, P = 0.035), a shorter duration from the onset of symptoms to the diagnosis of DM (2.5 vs 10 months, P = 0.003), and higher erythrocyte sedimentation rate (ESR) levels (23 vs 10 mm/h, P = 0.048) were found to be associated with an increased risk of malignancy. Conversely, the presence of Gottron's papules (63% vs 20%, P = 0.029) may suggest a lower likelihood of malignancy. The literature review revealed that the prevalence of myositis-associated malignancy was 40.7% (340/836), with variations ranging from 19% to 82.9% across different series. In summary, factors such as age over 65 years, a shorter duration between symptom onset and diagnosis of DM, and elevated ESR levels may indicate an increased risk of malignancy in anti-TIF1 gamma DM patients.
引用
收藏
页码:1646 / 1657
页数:12
相关论文
共 32 条